

Brian C Healy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/130265/publications.pdf>

Version: 2024-02-01

151
papers

6,784
citations

101543

36
h-index

76900

74
g-index

154
all docs

154
docs citations

154
times ranked

10593
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2333-2344.	27.0	1,102
2	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. <i>Science</i> , 2022, 375, 296-301.	12.6	892
3	Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort. <i>JAMA Neurology</i> , 2015, 72, 152.	9.0	328
4	Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. <i>American Heart Journal</i> , 2015, 170, 1105-1115.	2.7	213
5	Smoking and Disease Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 858-64.	4.5	182
6	Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events. <i>JAMA Internal Medicine</i> , 2014, 174, 927.	5.1	161
7	A probiotic modulates the microbiome and immunity in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 1147-1161.	5.3	158
8	Relationships between positive psychological constructs and health outcomes in patients with cardiovascular disease: A systematic review. <i>International Journal of Cardiology</i> , 2015, 195, 265-280.	1.7	137
9	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 58.	9.0	135
10	Clinical and MRI phenotype of children with MOG antibodies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 174-184.	3.0	130
11	Feasibility and utility of positive psychology exercises for suicidal inpatients. <i>General Hospital Psychiatry</i> , 2014, 36, 88-94.	2.4	128
12	Exploration of machine learning techniques in predicting multiple sclerosis disease course. <i>PLoS ONE</i> , 2017, 12, e0174866.	2.5	122
13	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1478-1491.	3.7	115
14	Gut Microbiome in Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 1195-1211.	5.3	115
15	Investigation of probiotics in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 58-63.	3.0	112
16	Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis. , 2011, 21, e50-e56.		98
17	Effect of gender on late-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1472-1479.	3.0	96
18	The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. <i>BMC Neurology</i> , 2019, 19, 23.	1.8	93

#	ARTICLE	IF	CITATIONS
19	Correlating serum micrnas and clinical parameters in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018, 58, 261-269.	2.2	78
20	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e267.	6.0	77
21	Text Message Interventions for Physical Activity: A Systematic Review and Meta-Analysis. <i>American Journal of Preventive Medicine</i> , 2020, 58, 142-151.	3.0	69
22	Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2016, 22, 935-943.	3.0	64
23	Identification of MS-specific serum miRNAs in an international multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e491.	6.0	59
24	Optimizing a Positive Psychology Intervention to Promote Health Behaviors After an Acute Coronary Syndrome: The Positive Emotions After Acute Coronary Events III (PEACE-III) Randomized Factorial Trial. <i>Psychosomatic Medicine</i> , 2018, 80, 526-534.	2.0	56
25	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. <i>Neurology</i> , 2014, 82, 2173-2179.	1.1	54
26	Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale. <i>Archives of Neurology</i> , 2008, 65, 1449.	4.5	53
27	Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2012, 22, e12-9.	2.0	53
28	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. <i>JAMA Neurology</i> , 2017, 74, 275.	9.0	52
29	Depression and fatigue in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 380, 236-241.	0.6	52
30	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. <i>Multiple Sclerosis Journal</i> , 2020, 26, 177-187.	3.0	49
31	Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2016, 26, 62-67.	2.0	48
32	Effect of vitamin D on MS activity by disease-modifying therapy class. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e167.	6.0	47
33	Diet pattern and prodromal features of Parkinson disease. <i>Neurology</i> , 2020, 95, e2095-e2108.	1.1	45
34	Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2019, 123, 1906-1914.	1.6	43
35	Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1841-1849.	3.0	41
36	Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-9.	0.8	38

#	ARTICLE	IF	CITATIONS
37	Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 354-361.	3.0	37
38	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. <i>Npj Digital Medicine</i> , 2019, 2, 123.	10.9	35
39	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	3.7	35
40	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2017, 27, 481-485.	2.0	34
41	MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 346, 250-254.	0.6	31
42	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. <i>Journal of Psychosomatic Research</i> , 2020, 138, 110252.	2.6	31
43	The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study. <i>Clinical Trials</i> , 2017, 14, 128-139.	1.6	30
44	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 119-127.	2.0	30
45	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1381-1390.	3.0	29
46	MRI phenotypes in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e530.	6.0	28
47	Treatment Satisfaction in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2014, 16, 68-75.	1.0	28
48	Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis. <i>American Journal of Ophthalmology</i> , 2016, 165, 54-64.	3.3	26
49	Reserve and Reserve-building activities research: key challenges and future directions. <i>BMC Neuroscience</i> , 2016, 17, 62.	1.9	26
50	Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. <i>Value in Health</i> , 2016, 19, 185-191.	0.3	26
51	Associations Between Psychological Constructs and Cardiac Biomarkers After Acute Coronary Syndrome. <i>Psychosomatic Medicine</i> , 2017, 79, 318-326.	2.0	26
52	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1708-1718.	3.0	25
53	Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30639-30648.	7.1	25
54	Age Differences in the Use of Health Information Technology Among Adults in the United States: An Analysis of the Health Information National Trends Survey. <i>Journal of Aging and Health</i> , 2021, 33, 147-154.	1.7	25

#	ARTICLE	IF	CITATIONS
55	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2425-2432.	3.6	24
56	Relationship of optimism and suicidal ideation in three groups of patients at varying levels of suicide risk. <i>Journal of Psychiatric Research</i> , 2016, 77, 76-84.	3.1	24
57	Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 273-277.	2.0	24
58	History of fatigue in multiple sclerosis is associated with grey matter atrophy. <i>Scientific Reports</i> , 2019, 9, 14781.	3.3	24
59	The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. <i>Quality of Life Research</i> , 2012, 21, 1677-1684.	3.1	23
60	Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1105-1114.	3.0	23
61	Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1275-1278.	5.8	23
62	Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors. <i>Journal of Neuroimaging</i> , 2015, 25, 191-199.	2.0	22
63	T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. <i>BMC Neurology</i> , 2015, 15, 124.	1.8	21
64	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. <i>NeuroImage: Clinical</i> , 2015, 8, 606-610.	2.7	21
65	Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2012, 46, 506-511.	2.2	20
66	Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. <i>Neurology</i> , 2017, 88, 677-684.	1.1	20
67	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 383, 221-229.	0.6	20
68	Adipokines are associated with pediatric multiple sclerosis risk and course. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101384.	2.0	20
69	A method for evaluating treatment switching criteria in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1483-1489.	3.0	19
70	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	17
71	A positive psychology-motivational interviewing program to promote physical activity in type 2 diabetes: The BEHOLD-16 pilot randomized trial. <i>General Hospital Psychiatry</i> , 2021, 68, 65-73.	2.4	17
72	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. <i>ENeurologicalSci</i> , 2018, 12, 42-46.	1.3	16

#	ARTICLE	IF	CITATIONS
73	Time between expanded disability status scale (EDSS) scores. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 98-103.	2.0	16
74	Feasibility and preliminary efficacy of a positive psychology-based intervention to promote health behaviors in heart failure: The REACH for Health study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110285.	2.6	16
75	The Loyalty Continuum: Differentiating Between Stages of Loyalty Development. <i>Journal of Marketing Theory and Practice</i> , 2014, 22, 367-384.	4.3	15
76	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 47-53.	2.0	15
77	Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. <i>PLoS ONE</i> , 2018, 13, e0206939.	2.5	15
78	The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. <i>Neurology</i> , 2015, 85, 1209-1213.	1.1	14
79	The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. <i>BMC Medical Imaging</i> , 2016, 16, 56.	2.7	14
80	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2018, 392, 94-99.	0.6	14
81	Randomized controlled trial of a well-being intervention in cardiac patients. <i>General Hospital Psychiatry</i> , 2019, 61, 116-124.	2.4	14
82	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 403, 38-43.	0.6	14
83	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 2276-2279.	2.4	14
84	Altruism and health outcomes in multiple sclerosis: The effect of cognitive reserve. <i>Journal of Positive Psychology</i> , 2013, 8, 144-152.	4.0	13
85	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 196-201.	2.0	13
86	MRI activity in MS and completed pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	13
87	A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. <i>Multiple Sclerosis Journal</i> , 2020, 26, 725-734.	3.0	13
88	The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2016, 26, 184-187.	2.0	12
89	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 971-980.	1.6	12
90	Is it better to cultivate positive affect or optimism? Predicting improvements in medical adherence following a positive psychology intervention in patients with acute coronary syndrome. <i>General Hospital Psychiatry</i> , 2019, 61, 125-129.	2.4	12

#	ARTICLE	IF	CITATIONS
91	A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. <i>Metabolites</i> , 2020, 10, 99.	2.9	12
92	Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. <i>Multiple Sclerosis Journal</i> , 2010, 16, 840-847.	3.0	11
93	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. <i>Journal of Neuroimaging</i> , 2020, 30, 212-218.	2.0	11
94	Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 92, 87-96.	5.3	11
95	Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 598-606.	2.0	10
96	A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 396-403.	1.6	10
97	Does timeframe adjustment of the Life Orientation Test-Revised assess optimism as a state?. <i>Journal of Positive Psychology</i> , 2019, 14, 799-806.	4.0	10
98	Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. <i>Journal of Neurology</i> , 2011, 258, 1812-1819.	3.6	9
99	Progression rates and sample size estimates for PPMS based on the CLIMB study population. <i>Multiple Sclerosis Journal</i> , 2015, 21, 180-188.	3.0	9
100	Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients. <i>Artificial Intelligence in Medicine</i> , 2015, 65, 79-88.	6.5	9
101	Risk attitudes and risk perceptions in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731666540.	1.0	9
102	An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 531-538.	3.6	9
103	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1791-1799.	3.0	9
104	State gratitude for one's life and health after an acute coronary syndrome: Prospective associations with physical activity, medical adherence and re-hospitalizations. <i>Journal of Positive Psychology</i> , 2019, 14, 283-291.	4.0	9
105	Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 631-638.	3.7	9
106	Modeling disease state transition heterogeneity through Bayesian variable selection. <i>Statistics in Medicine</i> , 2009, 28, 1353-1368.	1.6	8
107	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. <i>NeuroImage</i> , 2015, 119, 81-88.	4.2	8
108	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. <i>Journal of the Neurological Sciences</i> , 2018, 394, 127-131.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 593-602.	3.0	8
110	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	2.0	8
111	Randomized Study of Bedside vs Hallway Rounding. <i>Neurology</i> , 2021, 97, 434-442.	1.1	8
112	Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011, 303, 109-113.	0.6	7
113	Whole-brain atrophy assessed by proportional-versus registration-based pipelines from 3T MRI in multiple sclerosis. <i>Brain and Behavior</i> , 2018, 8, e01068.	2.2	7
114	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982840.	1.0	7
115	Return to College After a First Episode of Psychosis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, sgaa041.	1.7	7
116	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110155.	1.0	7
117	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101944.	2.0	7
118	The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2016, 7, 99.	2.4	6
119	Food allergies are associated with increased disease activity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 629-635.	1.9	6
120	Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 179-184.e3.	1.9	6
121	Machine and deep learning in MS research are just powerful statistics – No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 663-664.	3.0	6
122	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. <i>Quality of Life Research</i> , 2022, 31, 1799-1805.	3.1	6
123	Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1126-1130.	3.0	5
124	Developing a Psychological Behavioral Intervention in Cardiac Patients Using the Multiphase Optimization Strategy: Lessons Learned From the Field. <i>Annals of Behavioral Medicine</i> , 2020, 54, 151-163.	2.9	5
125	Exploring the feasibility and impact of positive psychology-motivational interviewing interventions to promote positive affect and physical activity in type 2 diabetes: design and methods from the BEHOLD-8 and BEHOLD-16 clinical trials. <i>Health Psychology and Behavioral Medicine</i> , 2020, 8, 398-422.	1.8	5
126	Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1011-1021.	2.8	5

#	ARTICLE	IF	CITATIONS
127	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110075.	1.0	5
128	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199907.	1.0	4
129	Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T _H cells. <i>IScience</i> , 2021, 24, 103347.	4.1	4
130	Domain Induced Dirichlet Mixture of Gaussian Processes: An Application to Predicting Disease Progression in Multiple Sclerosis Patients. , 2015, , .		3
131	Predictors of completion of a psychological-behavioral intervention in acute coronary syndrome patients. <i>Journal of Psychosomatic Research</i> , 2018, 112, 9-12.	2.6	3
132	Serum NFL levels in the first five years predict 10-year thalamic fraction in patients with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110693.	1.0	3
133	An Adaptive, Algorithm-based Text Message Intervention to Promote Health Behavior Adherence in Type 2 Diabetes: Treatment Development and Proof-of-Concept Trial. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 364-373.	2.2	3
134	Accommodating Uncertainty in a Tree Set for Function Estimation. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2008, 7, Article5.	0.6	2
135	Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 278, 54-59.	0.6	2
136	Joint assessment of dependent discrete disease state processes. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1182-1198.	1.5	2
137	Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110108.	1.0	2
138	Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103311.	2.0	2
139	Off-Label Use of Recombinant FVIIa: Clinical Characteristics That May Influence Outcomes.. <i>Blood</i> , 2005, 106, 431-431.	1.4	2
140	Demand with low supply: A pipeline for personalized integrative medicine in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103493.	2.0	2
141	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211049.	1.0	2
142	A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-7.	0.8	1
143	Study of serum microrna expression in amyotrophic lateral sclerosis patients: The challenge of selecting suitable internal control for normalization. <i>Muscle and Nerve</i> , 2019, 59, E3-E4.	2.2	1
144	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102910.	2.0	1

#	ARTICLE	IF	CITATIONS
145	Removing Confounding Factors via Constraint Based Clustering: An Application to Finding Homogeneous Groups of Multiple Sclerosis Patients. , 2013, , .		0
146	Does early (treatment in) BENEFIT lead to late MS benefit?. Neurology, 2016, 87, 970-971.	1.1	0
147	Response to Letter to the Editor: "Real-World Considerations for Applicability of Text Message Interventions for Promotion of Physical Activity" American Journal of Preventive Medicine, 2020, 59, e93-e94.	3.0	0
148	Predictors of completion and response to a psychological intervention to promote health behavior adherence in heart failure. International Journal of Psychiatry in Medicine, 2022, 57, 21-34.	1.8	0
149	Individual differences in self-rated anxiety and respiratory sinus arrhythmia predict performance on a complex working memory task. Cognition, Brain, Behavior an Interdisciplinary Journal, 2019, 23, 145-255.	0.1	0
150	Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, 2020, 1-7.	0.8	0
151	Text message preferences among individuals with type 2 diabetes: A brief report of an online survey study. Current Psychology, 0, , .	2.8	0